"The Mood Boosting Medicines: A New Frontier for Mental Health" Research from Griffith University has revealed an unexpected benefit of GLP 1 medications, commonly used to treat diabetes and obesity.
In a study involving nearly 15,000 people with bipolar disorder, those taking semaglutide (Ozempic or Wegovy) had a significantly lower risk of psychiatric hospitalization – a 21% reduction.
This finding has significant implications for the mental health community. For years, researchers have sought effective treatments to stabilize mood and reduce relapse rates in individuals with bipolar disorder.